Industry: Pharmaceuticals, Biotechnology
Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer. Ambit plans to initiate clinical trials in 2006 for AC220, its selective class III receptor tyrosine kinase inhibitor that will initially be tested in patients with acute myeloid leukemia. Ambit’s proprietary kinase profiling technology, KinomeScan, is designed to be integrated across all stages of the drug discovery and development process and has been validated through collaborations with Roche, Bristol-Myers Squibb Company, GlaxoSmithKline, Cephalon and ( www.ambitbio.com )
Ambit Biosciences Corporation
4215 Sorrento Valley Blvd.
San Diego, California 92121
USA
Tel: (858) 334-2100
Fax: (858) 334-2199